Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies (Q37235541)

19 August 2017

1 reference

title

Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies (English)

1 reference

19 August 2017

1 reference

Ellen M Tedaldi

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Journal of Addictive Diseases

19 August 2017

published in

1 reference

19 August 2017

volume

27

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

83-91

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Assessment of efficacy of treatment in HCV: infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Hepatitis C Virus Replication in Transfected and Serum-Infected Cultured Human Fetal Hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Treating HCV with ribavirin analogues and ribavirin-like molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Development of prophylactic and therapeutic vaccines against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

The survival benefits of AIDS treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_10

21 January 2018

Identifiers

DOI

10.1300/J069V27N02_10

1 reference

19 August 2017

1 reference